Prices of CD4 assays and viral load tests must be reduced for developing countriesBMJ 2001; 323 doi: http://dx.doi.org/10.1136/bmj.323.7316.809b (Published 06 October 2001) Cite this as: BMJ 2001;323:809
- Courtenay Bartholomew, emeritus professor of medicine ([email protected])
- 7 Queens Park East, Port of Spain, Trinidad, West Indies
EDITOR—Wise has reported that GlaxoSmithKline is to cut the price of some drugs in developing countries.1 For over a decade antiretroviral treatment has been available to patients in the United States and Europe. Because of the extent of HIV infection in the developing world, however, the cost of these drugs was way beyond the reach of the government treasuries in the world's poorest countries. As a result there was the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial